Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
about
Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approachGlobal chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1.Wound macrophages as key regulators of repair: origin, phenotype, and functionChemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury.Polymorphisms in chemokine and chemokine receptor genes and the development of coal workers' pneumoconiosisPathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions.Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activityCX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease.Chemokines and chemokine receptors in scleroderma.Upregulation of fractalkine contributes to the proliferative response of prostate cancer cells to hypoxia via promoting the G1/S phase transition.Increased serum levels of fractalkine and mobilisation of CD34+CD45- endothelial progenitor cells in systemic sclerosis.The human cutaneous chemokine system.Chemokines and skin diseases.Synergistic induction of CX3CL1 by TNF alpha and IFN gamma in osteoblasts from rheumatoid arthritis: involvement of NF-kappa B and STAT-1 signaling pathways.Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis.The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration.Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.The cytokine language of monocytes and macrophages in systemic sclerosis.Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases.
P2860
Q24814682-11C29B8F-2F62-4FCB-B97B-95C002E19899Q33826259-0C89B194-F369-47F8-AF68-D42C06CEA313Q34391705-3667F124-4F61-4881-8DCF-DDA567097568Q34755904-778AC756-4A9F-4E63-ACB9-EF27EA05664EQ35221957-5ACB7EC2-E46F-4145-952B-1DB338BDCCBDQ35879555-2382E135-2B4B-47A5-B2E0-3121C0DC1755Q35927383-609F1AC9-1780-4B6B-8A3D-A77B0B03B0FFQ36245680-62911945-9473-4891-B5BF-321C0D471306Q36255118-54E79879-D2DD-4383-BBDB-93A8FF5AC391Q36372735-C6535DFD-4E6C-4CDB-BDEF-A5B2465DCA5EQ36521144-6418DFDB-A123-4FF1-AB52-A6264B41A1A4Q36592493-CA297EF7-15F1-4A08-BE98-B8EB8A10AB9FQ37713525-DE21D704-58CB-4809-8EC2-15D7FFDC71ABQ38008335-2ED1B151-D44C-4F9B-A1A9-B0A4A56319B6Q38245643-9BA781CA-EC5C-40BE-9288-49AADE0AA299Q38294927-798BE731-9F93-4328-A5B6-4EC0D5F57A78Q41534964-36126986-CD29-46B2-B386-878B12D1D039Q42066582-8FCAAC79-C455-4889-9989-C565B2C88785Q42154373-7BA8DB9E-5381-418E-B264-031D8F2508AEQ42345689-905860B5-3264-41E7-842A-9B8F012DD8A6Q42452543-DB658921-ACFA-4541-AECC-2F5568561982
P2860
Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Up regulated expression of fra ...... ients with systemic sclerosis.
@ast
Up regulated expression of fra ...... ients with systemic sclerosis.
@en
type
label
Up regulated expression of fra ...... ients with systemic sclerosis.
@ast
Up regulated expression of fra ...... ients with systemic sclerosis.
@en
prefLabel
Up regulated expression of fra ...... ients with systemic sclerosis.
@ast
Up regulated expression of fra ...... ients with systemic sclerosis.
@en
P2093
P2860
P356
P1476
Up regulated expression of fra ...... ients with systemic sclerosis.
@en
P2093
P2860
P356
10.1136/ARD.2003.018705
P407
P577
2005-01-01T00:00:00Z